Literature DB >> 21385991

Apolipoprotein E isoform-dependent microglia migration.

Eiron Cudaback1, Xianwu Li, Kathleen S Montine, Thomas J Montine, C Dirk Keene.   

Abstract

Complement component C5a and ATP are potent effectors of microglial movement and are increased in diverse neurodegenerative diseases and at sites of injury. Apolipoprotein E (apoE) influences microglial function, and different human apoE isoforms confer variable risk for development of neurodegenerative disorders, especially Alzheimer's disease. The purpose of this investigation was to test the hypothesis that mouse apoE and human apoE isoforms influence microglial migration. Using primary wild-type and apoE-deficient microglia, we show that C5a- and ATP-stimulated chemotaxis are largely apoE-dependent processes with different molecular bases. Although the C5a-dependent chemotaxis of wild-type microglia was completely blocked by receptor-associated protein (RAP), suggesting apoE receptor involvement, ATP-stimulated migration was unaffected by RAP but was associated with differential ERK phosphorylation. Studies using primary microglia derived from targeted replacement mice "humanized" for the coding exons (protein isoform) of human ε2 (apoE2), ε3 (apoE3), or ε4 (apoE4) allele of APOE revealed that primary mouse microglia expressing apoE4 or apoE2 exhibited significantly reduced C5a- and ATP-stimulated migration compared with microglia expressing human apoE3. This study, for the first time, demonstrates apoE dependence and apoE isoform-specific modulation of microglial migration in response to distinct chemotactic stimuli commonly associated with neurodegenerative disease.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21385991      PMCID: PMC3101033          DOI: 10.1096/fj.10-176891

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  66 in total

1.  ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum.

Authors:  Haim Belinson; Daniel M Michaelson
Journal:  J Neural Transm (Vienna)       Date:  2009-04-16       Impact factor: 3.575

2.  Microglial activation and chronic neurodegeneration.

Authors:  Melinda E Lull; Michelle L Block
Journal:  Neurotherapeutics       Date:  2010-10       Impact factor: 7.620

3.  Human apolipoprotein E2, E3, and E4 isoform-specific transgenic mice: human-like pattern of glial and neuronal immunoreactivity in central nervous system not observed in wild-type mice.

Authors:  P T Xu; D Schmechel; T Rothrock-Christian; D S Burkhart; H L Qiu; B Popko; P Sullivan; N Maeda; A M Saunders; A D Roses; J R Gilbert
Journal:  Neurobiol Dis       Date:  1996       Impact factor: 5.996

4.  Microglial C5aR (CD88) expression correlates with amyloid-beta deposition in murine models of Alzheimer's disease.

Authors:  Rahasson R Ager; Maria I Fonseca; Shu-Hui Chu; Sam D Sanderson; Stephen M Taylor; Trent M Woodruff; Andrea J Tenner
Journal:  J Neurochem       Date:  2010-02-02       Impact factor: 5.372

5.  The low-density lipoprotein receptor-related protein 1 mediates tissue-type plasminogen activator-induced microglial activation in the ischemic brain.

Authors:  Chen Zhang; Jie An; Dudley K Strickland; Manuel Yepes
Journal:  Am J Pathol       Date:  2009-01-15       Impact factor: 4.307

Review 6.  Functions of C5a receptors.

Authors:  Peter A Ward
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

7.  APOE genotype-specific differences in human and mouse macrophage nitric oxide production.

Authors:  Carol A Colton; Leila K Needham; Candice Brown; Danielle Cook; Karima Rasheed; James R Burke; Warren J Strittmatter; Donald E Schmechel; Michael P Vitek
Journal:  J Neuroimmunol       Date:  2004-02       Impact factor: 3.478

8.  Protective effect of C5a receptor inhibition after murine reperfused stroke.

Authors:  Grace H Kim; J Mocco; David K Hahn; Christopher P Kellner; Ricardo J Komotar; Andrew F Ducruet; William J Mack; E Sander Connolly
Journal:  Neurosurgery       Date:  2008-07       Impact factor: 4.654

Review 9.  P2Y and P2X purinoceptor mediated Ca2+ signalling in glial cell pathology in the central nervous system.

Authors:  Greg James; Arthur M Butt
Journal:  Eur J Pharmacol       Date:  2002-07-05       Impact factor: 4.432

10.  Minocycline delays disease onset and mortality in a transgenic model of ALS.

Authors:  Ludo Van Den Bosch; Petra Tilkin; Griet Lemmens; Wim Robberecht
Journal:  Neuroreport       Date:  2002-06-12       Impact factor: 1.837

View more
  24 in total

Review 1.  New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors.

Authors:  Ross Corriden; Paul A Insel
Journal:  Purinergic Signal       Date:  2012-04-15       Impact factor: 3.765

2.  In Vivo Chimeric Alzheimer's Disease Modeling of Apolipoprotein E4 Toxicity in Human Neurons.

Authors:  Ramsey Najm; Kelly A Zalocusky; Misha Zilberter; Seo Yeon Yoon; Yanxia Hao; Nicole Koutsodendris; Maxine Nelson; Antara Rao; Alice Taubes; Emily A Jones; Yadong Huang
Journal:  Cell Rep       Date:  2020-07-28       Impact factor: 9.423

3.  Differential relationships of reactive astrocytes and microglia to fibrillar amyloid deposits in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Alona Muzikansky; Teresa Gómez-Isla; John H Growdon; Rebecca A Betensky; Matthew P Frosch; Bradley T Hyman
Journal:  J Neuropathol Exp Neurol       Date:  2013-06       Impact factor: 3.685

4.  Apolipoprotein E mediation of neuro-inflammation in a murine model of multiple sclerosis.

Authors:  Soomin Shin; Katharine A Walz; Angela S Archambault; Julia Sim; Bryan P Bollman; Jessica Koenigsknecht-Talboo; Anne H Cross; David M Holtzman; Gregory F Wu
Journal:  J Neuroimmunol       Date:  2014-03-29       Impact factor: 3.478

5.  Human Striatal Dopaminergic and Regional Serotonergic Synaptic Degeneration with Lewy Body Disease and Inheritance of APOE ε4.

Authors:  Nadia Postupna; Caitlin S Latimer; Eric B Larson; Emily Sherfield; Julie Paladin; Carol A Shively; Matthew J Jorgensen; Rachel N Andrews; Jay R Kaplan; Paul K Crane; Kathleen S Montine; Suzanne Craft; C Dirk Keene; Thomas J Montine
Journal:  Am J Pathol       Date:  2017-02-16       Impact factor: 4.307

6.  APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease.

Authors:  Yue Yang; Eiron Cudaback; Nikolas L Jorstad; Jake F Hemingway; Catherine E Hagan; Erica J Melief; Xianwu Li; Tom Yoo; Shawn B Khademi; Kathleen S Montine; Thomas J Montine; C Dirk Keene
Journal:  Am J Pathol       Date:  2013-07-04       Impact factor: 4.307

7.  Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease.

Authors:  Alberto Serrano-Pozo; Rebecca A Betensky; Matthew P Frosch; Bradley T Hyman
Journal:  Am J Pathol       Date:  2015-12-11       Impact factor: 4.307

Review 8.  ApoE and Aβ in Alzheimer's disease: accidental encounters or partners?

Authors:  Takahisa Kanekiyo; Huaxi Xu; Guojun Bu
Journal:  Neuron       Date:  2014-02-19       Impact factor: 17.173

9.  APOE genotype-dependent modulation of astrocyte chemokine CCL3 production.

Authors:  Eiron Cudaback; Yue Yang; Thomas J Montine; C Dirk Keene
Journal:  Glia       Date:  2014-08-04       Impact factor: 7.452

10.  A phenotypic change but not proliferation underlies glial responses in Alzheimer disease.

Authors:  Alberto Serrano-Pozo; Teresa Gómez-Isla; John H Growdon; Matthew P Frosch; Bradley T Hyman
Journal:  Am J Pathol       Date:  2013-04-18       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.